MacroGenics Provides Update on Corporate Progress and 2020 Financial Results
February 25, 2021 16:01 ET
|
MacroGenics, Inc.
MARGENZA™ approved in December 2020; commercial launch expected March 2021July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumabMultiple clinical updates across...
MacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
February 18, 2021 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 18, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Names Federica O’Brien to its Board of Directors
February 11, 2021 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
February 11, 2021 07:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
February 08, 2021 07:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 08, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA™ in JAMA Oncology
January 25, 2021 07:30 ET
|
MacroGenics, Inc.
Primary endpoint of Phase 3 study met with MARGENZA (margetuximab-cmkb) showing a 24% Progression Free Survival (PFS) relative risk reduction compared to Herceptin® (trastuzumab), both with...
MacroGenics to Participate in Upcoming Investor Conferences
January 11, 2021 08:45 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Jan. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces MGD019 Publication in Cell Reports Medicine
December 22, 2020 11:35 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Dec. 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule
December 18, 2020 07:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Dec. 18, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
December 16, 2020 16:30 ET
|
MacroGenics, Inc.
MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® (trastuzumab), both combined with chemotherapy, in a head-to-head...